IPOX® Associate Lukas Muehlbauer was cited by Reuters on Kardigan’s planned U.S. IPO, which targets a valuation of up to $1.4 billion and aims to raise as much as $373.3 million. Muehlbauer noted a “clear uptick in biotech IPOs” and said healthcare IPO activity has already surpassed last year’s deal flow, signaling an open window for the sector. He also cautioned that investors remain selective, favoring companies with clinical progress and clearer paths to FDA approval.

IPOX® Associate Muehlbauer was interviewed for ZEIT ONLINE, the digital news platform of the German weekly newspaper DIE ZEIT, on the market impact of major planned IPOs and new share offerings. He discussed SpaceX’s expected $75 billion raise, possible listings from leading AI companies, and the challenge of absorbing significant new equity supply. He also noted that later insider sales may be the more important liquidity test for investors after the initial IPO.

IPOX® Associate Dr. Lukas Muehlbauer was quoted by Reuters on ERock’s NYSE debut after the gas generator maker’s shares opened below their IPO price, valuing the company at $5.49 billion. Muehlbauer said investors were pushing back on valuation amid execution risk, noting that ERock’s growth angle is tied to a substantial backlog from data center power demand, but the market wants proof that backlog can convert into revenue before assigning the company a more premium public-market valuation after its listing.

IPOX® Associate Lukas Muehlbauer was quoted by Reuters on Parabilis Medicines’ upsized U.S. IPO, which targets a valuation of nearly $2.3 billion as biotech listings regain momentum. Muehlbauer said the larger offering signals a healthier biotech IPO pipeline, while noting investors remain selective and favor larger, better-backed deals. He also highlighted Parabilis’ Regeneron partnership as an external validation of the company’s technology and a source of added credibility ahead of its expected Nasdaq debut under ticker PBLS.

IPOX® CEO Josef Schuster was featured in Reuters’ View article on OpenAI’s confidential U.S. IPO filing, which examined how major AI companies are moving toward public markets. Schuster commented that SpaceX, OpenAI, and Anthropic are seeking public-market capital to finance significant growth, while noting that investors may both reward and punish these companies as their fundamentals develop. He also highlighted that their offering size and initial float could make post-listing trading highly dynamic over time for investors and markets alike.